Prescription drug · BLA
Anktiva (Nogapendekin alfa inbakicept-pmln) NDC 81481-803
Nogapendekin alfa inbakicept-pmln 400 ug/.4mL · Solution · Intravesical · Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 81481-803-01 | 81481080301 | 1 VIAL, GLASS in 1 BOX (81481-803-01) / .4 mL in 1 VIAL, GLASSMarketed from May 6, 2024 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Anktiva
- Generic name (nonproprietary)
- nogapendekin alfa inbakicept-pmln
- Active ingredients
- Nogapendekin alfa inbakicept-pmln — 400 ug/.4mL
- Dosage form
- Solution
- Route
- Intravesical
- Labeler
- Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.NDC labeler code 81481
- Product type
- Prescription drug
- Marketing category
- BLA — Biologics License ApplicationApplication BLA 761336
- Marketing start
- Listing expires
- Other FDA classes
- Interleukin-15 Receptor Agonists (Mechanism)
- Identifiers
- Product ID 81481-803_3851a6cd-d487-2012-e063-6394a90aa33eSPL ID 3851a6cd-d487-2012-e063-6394a90aa33eSPL set ID eae31db8-3e7a-d9e0-708d-74419d1b50ffRxCUI 2682684, 2682691UNII 7TK323DLA0
- Pharmacologic class
- Interleukin-15 Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.
- NDC on a medical claim
N481481080301followed by a unit qualifier and the quantityPackage 81481-0803-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ANKTIVA is an interleukin-15 (IL-15) receptor agonist indicated with Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. ( 1 )
Excerpt only. Read the full label for complete information.
About NDC 81481-803
- What is NDC 81481-803?
- 81481-803 is the product NDC for Anktiva (nogapendekin alfa inbakicept-pmln), Nogapendekin alfa inbakicept-pmln 400 ug/.4mL solution, listed with the FDA by Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc.. It has 1 package NDC, shown above in 10- and 11-digit form.
- What drug is associated with this NDC?
- Anktiva (Nogapendekin alfa inbakicept-pmln).
- What is the active ingredient?
- Nogapendekin alfa inbakicept-pmln.
- Who is the labeler?
- Altor BioScience, LLC, an indirect wholly-owned subsidiary of ImmunityBio, Inc., NDC labeler code 81481. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
- What other NDCs exist for Anktiva?
- None: this is the only finished product listed under this name.
- Is there a related HCPCS / J-code?
- Not in Med-Code's curated HCPCS directory. See Billing references above.